Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026American Journal of Hematology

The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta‐Analysis of the European Myeloma Network ( EMN )

View Full Paper
Ask AI
Bookmark
Share

Authors

HLHeinz LudwigETEvangelos TerposFGFrancesca Gay

Discussion

Loading...

Member takes

Overview

Systematic review and network meta-analysis reveal therapy impacts progression-free and overall survival in newly diagnosed multiple myeloma patients.

Key Points

  • This review aims to analyze the effects of maintenance therapies on progression-free and overall survival in newly diagnosed multiple myeloma patients.
  • Conducted a comprehensive systematic review of maintenance therapy studies
  • Aggregated data through meta- and network meta-analyses
  • Evaluated therapeutic regimens including lenalidomide, proteasome inhibitors, and CD38 antibodies.
  • Daratumumab–lenalidomide showed the highest progression-free survival benefit compared to observation.
  • Overall survival benefit was significant with lenalidomide alone in transplant-eligible patients (TE).
  • CD38 therapy trended towards improved overall survival, unlike proteasome inhibitors.

Cite This Study

Ludwig et al. (2026) studied this question.

synapsesocial.com/papers/6a362f92db0793dc1a53707fhttps://doi.org/10.1002/ajh.70397
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The role of maintenance therapy and its cessation in patients with multiple myeloma2025
  2. 2Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese2025
  3. 3Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  4. 4RoB 2: a revised tool for assessing risk of bias in randomised trials2019 · 33,351 citations
  5. 5How to perform a meta-analysis with R: a practical tutorial2019 · 5,974 citations